Introduction {#sec0005}
============

Incidence of nontuberculous mycobacterial (NTM) infections has significantly increased during the past decades \[[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025]\]. Male patients older than 50 years with alcohol abuse, COPD, smoking or previous pulmonary tuberculosis are associated with high risks of infection \[[@bib0030], [@bib0035], [@bib0040]\]. *Mycobacterium szulgai* is a scotochromogen of slow-growing NTM. It was first isolated in 1972 \[[@bib0005]\] [and to be a rare pathogen in human beings]{.ul} \[[@bib0030],[@bib0045],[@bib0050]\], [usually causing]{.ul} pulmonary infection similar to that caused by *M. tuberculosis* \[[@bib0055],[@bib0060]\]. Due to increasing reports of clinical disease related to *M. szulgai*, isolation of *M. szulgai* should be considered a significant pathogen.

The diagnosis of *M. szulgai* infection should be considered when it is isolated \[[@bib0060]\]. Disseminated *M. szulgai* infection is rarely reported. In the article, we summarize the literature on *M. szulgai* infection with disseminated presentations.

Case report {#sec0010}
-----------

A 71-year-old man with left nasal alar melanoma post wide excision with a nasolabial flap was admitted due to progressive left side costal pain associated with dyspnea. Physical examination revealed crackle breath sounds over the left lower lung field. [A chest X-ray revealed accumulated left pleural effusion and a chest CT scan showed left loculated pleural effusion with pleural thickening.]{.ul} Video-assisted thoracic surgery (VATS) with left side decortication was performed due to poor response to [piperacillin/tazobactam and imipenem/cilastatin. The pathological findings showed acute suppurative inflammation composed of dense neutrophilic and eosinophilic infiltration with extensive necrosis which indicated empyema and tissue culture did not yield bacterial or mycobacterial pathogens. Sputum and pleural effusion acid-fast stain also failed to identify specific pathogen.]{.ul} The patient received ciprofloxacin for pneumonia complicated with empyema. The fever episode subsided except dry cough and persistent pneumonia consolidation in the right upper lung field.

Progressive bilateral cervical lymphadenopathy was noticed by the patient one month after discharge ([Fig. 1](#fig0005){ref-type="fig"}A). [Additionally]{.ul}, abnormal granular nodules over nasopharynx were found by otolaryngologist during follow up for melanoma. Excisional biopsy of the left-side cervical lymph node was performed. [The pathological report showed ill-defined granulomatous inflammation (]{.ul}[Fig. 2](#fig0010){ref-type="fig"}A[), and acid-fast positive bacilli was identified (]{.ul}[Fig. 2](#fig0010){ref-type="fig"}B[).]{.ul} *[M. szulgai]{.ul}* [was also grown from]{.ul} the cervical lymph node. *M. szulgai* was isolated from the following three sets of sputum. [HIV screening was negative whereas anti-interferon-γ autoantibodies were positive.]{.ul}Fig. 1(A) Computed tomography (CT) of head and neck revealed multiple lymphadenopathy over bilateral cervical areas (arrowheads); (B) Resolved cervical lymphadenopathy after 16-month anti-tuberculous therapies.Fig. 1Fig. 2(A) Granulomatous formation with infiltrations of neutrophils and eosinophils in the left cervical lymph node biopsy (hematoxylin and eosin stain); (B) Acid-fast positive bacilli was found in the cervical lymph node.Fig. 2

Anti-mycobacterial combination therapies of clarithromycin, ethambutol, and [rifampin]{.ul} were administered. Clinical improvement of cervical lymphadenitis was noted during follow up. Sputum culture for [mycobacteria]{.ul} turned negative after five months of combination therapies. [Follow up]{.ul} chest X-ray showed gradual resolution of consolidation over the right upper lung field. The patient [is]{.ul} regularly followed up at the outpatient clinic [on the therapy planned for 12 months after the sputum culture turns negative.]{.ul}

Literature review {#sec0015}
-----------------

*M. szulgai* infection is less common among NTM species. [It presents with]{.ul} pulmonary involvement in most patients, indistinguishable with *[Mycobacterium tuberculosis]{.ul}* \[[@bib0055],[@bib0060]\]. Extrapulmonary infection of *M. szulgai* mainly included cutaneous infection, peripheral lymphadenitis, tenosynovitis, olecranon bursitis and osteomyelitis \[[@bib0035]\]. The disseminated infection had been rarely reported in immunocompromised patients. To identify the reported cases, we reviewed all case reports and case series through search engines of Pubmed and Google with the keyword of disseminated infection of *M. szulgai*. Disseminated infection was defined as involvements more than one site or organ of M. *szulgai* infection. The patients with a single site or organ involvement or absence of cultural evidence were excluded.

Results {#sec0020}
=======

Patient characteristics {#sec0025}
-----------------------

Of fifteen cases with disseminated *[M. szulgai]{.ul}* infection have been reported from 1984 to 2013. Twelve patients were male and three patients were female. The average age was [46 year old]{.ul}. There was a [four year old]{.ul} boy who suffered from cutaneous infection and lymphadenitis. Among the ten male patients, the average age was 42 years old ([Table 1](#tbl0005){ref-type="table"}). All three female patients were over 60 years old of age.Table 1Characteristics of the fifteen patients with disseminated *Mycobacterium szulgai* infection.Table 1First author/\
publish yearAge/SexComorbiditySite of infectionTreatment/durationOutcomeReference1Gur et al., 198418/MLymphocyte dysfunctionBone\
Skin, LNsINH, RIF, EMB/\> 2 YearsPersistent infection\[[@bib0115]\]2Cross et al., 198551/MSteroid useSkin, boneINH, RIF, EMB/ 24 monthsCure\[[@bib0125]\]3Roig et al., 199367/MHIVBone, kidneyStreptomycin, INH, Ethionamide/ unknown durationND\[[@bib0150]\]4.Luque et al., 199837/MAIDS, HBV, HCVBone, lung, bloodINH, EMB, Clofazimine/ 5 monthsDeath due to cryptococcal meningitis, liver failure\[[@bib0045]\]5Hurr and Sorg, 199868/FSteroid useBone, LNsSurgery\
INH, RIF / 1 monthCure\[[@bib0040]\]6Fang et al., 199959/MChemotherapyBone, LNsRIF, EMB, Ciprofloxacin/ 1 year; INH/ 6monthsCure\[[@bib0130]\]7Nakada et al., 200164/FMDSBone marrow, lungClarithromycin / unknown durationDeath due to myocardial infarction\[[@bib0070]\]8Frisk et al., 20034/MLeukemia status post bone marrow transplantationSkin, LNsRIF, EMB / 9 monthsCure\[[@bib0135]\]9Tappe et al., 200436/MAIDSSkin, boneSurgery\
Clarithromycin, EMB,\
Ciprofloxacin /1 yearCure\[[@bib0160]\]10Kapur et al., 200427/MUnknown immunosuppressionSkin, bone marrowINH, EMB, Clarithromycin/\
unknown durationCure\[[@bib0140]\]11Manalac et al., 200765/MCLL, lymphomaMultiple jointsI&D\
RIF, Levofloxacin, Clarithromycin/unknown durationDeath due to respiratory failure\[[@bib0075]\]12Meyer et al., 200866/FCLLSkin, boneRIF, INH, EMB/ 2 yearsDeath due to SDH\[[@bib0080]\]13Ohta et al., 201159/MHBV carrierSkin, lungRIF, INH, PZA, Streptomycin/unknown durationCure\[[@bib0145]\]14Riedel et al., 201259/MAMLBone marrow, LNsNo target treatmentDeath\[[@bib0065]\]15Shamriz et al., 201317/MPartial STAT1 deficiencyBone, LNsINH, RIF, EMB, PZA/ 2 months; RIF, EMB, Azithromycin/ \> 20 monthsCure\[[@bib0155]\][^1]

Site of infection {#sec0030}
-----------------

Among fifteen patients with disseminated *[M. szulgai]{.ul}* infection, the most commonly involved sites of infection were bone with skin (four patients) and bone with lymph nodes (four patients), followed by bone and pulmonary involvement (two patients). [For classification of]{.ul} involved sites, the bony involvement (12) was the most common, followed by skin (7) and lymph nodes (6) involvements. The results were significantly in contrast to single organ involvement in the general infected population with mainly pulmonary infection.

Among twelve male patients with [disseminated]{.ul} *[M. szulgai]{.ul}* infection, the most commonly involved sites or organs were bone (9), skin (5), and lymph nodes (5). Relatively rare infection sites included pulmonary involvement (2), joint (1), urinary tract (1) and bloodstream (1) involvement. Among three female patients, the most common infected sites were bone (3), respiratory tract (2), and skin (2). Besides, there is one case of [solitary]{.ul} lymph node involvement.

Patient comorbidities {#sec0035}
---------------------

The comorbidities were commonly associated with immunocompromised status including malignancy, HIV infection or AIDS, HBV or HCV carrier, usage of immunosuppressive agents or uncategorized immunosuppression. Interestingly, the underlying malignancy were all associated with neoplastic hematologic disorders. There were two patients undertaken long term steroids and one patient had received a [7-day-course of chemotherapy with cyclophosphamide, prednisolone, and vincristine.]{.ul}

Treatment and prognosis {#sec0040}
-----------------------

The optimal regimens for disseminated *M. szulgai* infection are uncertain during the past three decades \[[@bib0060]\]. Most patients received [rifampin]{.ul} and ethambutol-base combination therapy in our literature review, but the treatment duration was uncertain. Surgical intervention or incision and drainage was done in some patients with bony and joint involvement. Most patients reached clinical improvement or even complete remission. One patient died 20 days after admission due to a postmortem diagnosis of *M. szulgai* infection without target treatment \[[@bib0065]\]. Another patient died of complications related to the co-infection of cryptococcal meningitis and liver failure without adequate antimicrobial therapy \[[@bib0045]\].

There were three cases of fatality during follow up, which were not caused by *M. szulgai* infection itself or disease activity. A [64 year old]{.ul} woman with pulmonary and bone marrow involvement died of myocardial infarction three months after resolution of *[M. szulgai]{.ul}* infection \[[@bib0070]\]. A [65 year old]{.ul} man with disseminated joint involvement died of respiratory failure during the rehabilitation process \[[@bib0075]\]. Another [66 year old]{.ul} woman with skin and bone involvement of *M. szulgai* died from unrelated subdural hematoma two months after discontinuation of [anti-mycobacterial therapy]{.ul} \[[@bib0080]\].

Discussion {#sec0045}
==========

*M. szulgai* infection is recognized as a significant pathogen causing clinical [disease]{.ul}, although the disseminated infection is rare. The clinical, radiological and pathological presentations of *M. szulgai* infection are similar to *M. tuberculosis* infection \[[@bib0055],[@bib0060]\], but there is no evidence proved for person-to-person transmission \[[@bib0085]\]. The diagnosis of *M. szulgai* infection is based on clinical presentation, radiological and cultural specimens for mycobacteria. In contrast to other NTM viewed as an environmental contaminant, identification of *M. szulgai* should be considered a significant pathogen \[[@bib0060]\]. However, the classic cultural system for [mycobacteria species]{.ul} identification is time-consuming. Highly accurate nucleic acid probes are commercially available for isolation of *M. szulgai* and other NTM such as *Mycobacterium avium complex* (MAC) and *M. kansasii* within one day of identification \[[@bib0090]\].

Due to its rare prevalence, isolation of *M. szulgai* provides a pathological significance \[[@bib0060]\]. Pulmonary infection is the most common manifestation in a single site or organ involvement, and lymphadenitis, cutaneous or disseminated disease has been rarely reported \[[@bib0035]\]. However, among populations with disseminated *M. szulgai* in our study, the most commonly involved sites and organs included osteomyelitis, cutaneous involvement, and lymphadenopathy.

[Browne]{.ul} et al. [demonstrated t]{.ul}hat neutralizing anti--interferon-γ autoantibodies were detected in Asian adults with NTM infections \[[@bib0095]\]. Patients with anti--interferon-γ autoantibodies with impaired interferon-γ signaling were vulnerable to disseminated infections with intracellular pathogens, especially non-tuberculosis mycobacterium \[[@bib0095], [@bib0100], [@bib0105]\].

Our case had positive anti--interferon-γ autoantibodies which were considered to be associated with the adult-onset immunodeficiency syndrome, similar to that of advanced HIV infection. Treatment with EE-IFN-g might be worth investigating in patients producing anti--interferon-γ. Rituximab was under investigation for patients with relapsed anti--interferon-γ autoantibody-associated NTM infections \[[@bib0110]\].

Most patients reviewed in our study with disseminated *M. szulgai* infection responded well to rifampin and ethambutol based combination therapies \[[@bib0065]\]. Only one patient suffered from a persistent infection after at least a 24-month period of isoniazid, rifampin, and ethambutol \[[@bib0115]\].

Although *M. szulgai* is susceptible to most [anti-mycobacterial agents]{.ul}, no optimal agents and duration of treatment were well established. Current guidance recommends the combination therapy with [rifampin]{.ul}, ethambutol and a macrolide such as a clarithromycin for at least one year after sputum cultures turn negative \[[@bib0055],[@bib0060],[@bib0120]\]. Nevertheless, *[in vitro]{.ul}* [resistance to]{.ul} clarithromycin and ciprofloxacin have been reported \[[@bib0035],[@bib0115],[@bib0120]\].

Conclusion {#sec0050}
==========

For increasing reports of clinical diseases, the isolation of *M. szulgai* should be considered as a pathogen \[[@bib0060]\]. The patients with disseminated *M. szulgai* disease were relatively rare, and it was considered to be associated with adult-onset immunodeficiency syndrome. The combination therapies of anti-tuberculous agents should be administered for at least twelve months after the sputum culture turns negative.
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[^1]: HIV = human immunodeficiency virus; AIDS = acquired Immunodeficiency syndrome; MDS = myelodysplastic syndrome; HBV = hepatitis B virus; HCV = hepatitis C virus; CLL = chronic lymphocytic leukemia; AML*=*acute myeloid leukemia; STAT1=signal transducer and activator of transcription 1; LNs = lymph nodes; INH = isoniazid; RIF = rifampin; EMB = ethambutol; PZA = pyrazinamide; MI = myocardial infarction; SDH= subdural hematoma.
